Newsroom

Newsroom

amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy. Since 1985, amfAR has raised nearly $950 million in support of its programs and has awarded more than 3,800 grants to research teams worldwide.

Media Contacts

Events Coverage

Bennah Serfaty
Senior Director, Communications
(212) 806-1607
bennah.serfaty@amfar.org

External Communications

Robert Kessler
Manager, Program Communications
(212) 806-1602
robert.kessler@amfar.org

2025


­Statement from amfAR on FDA Approval of Lenacapavir for HIV Pre-Exposure Prophylaxis


NEW YORK, June 18, 2025 — The U.S. Food and Drug Administration (FDA) announced Thursday that it has approved the antiretroviral drug lenacapavir for use as HIV pre-exposure prophylaxis (PrEP). Twice-annual injection of lenacapavir was shown to be 100% effective at preventing HIV transmission in one clinical trial and was named Science’s Breakthrough of the Year in 2024. 

Read More.



2024


2023


2022


2021


2020


2019